|
1
|
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.
|
Kidney Int
|
2011
|
5.25
|
|
2
|
Long-term outcome of renal transplantation from older donors.
|
N Engl J Med
|
2006
|
5.10
|
|
3
|
Clinical practice. Nephropathy in patients with type 2 diabetes.
|
N Engl J Med
|
2002
|
3.57
|
|
4
|
Sodium intake, ACE inhibition, and progression to ESRD.
|
J Am Soc Nephrol
|
2011
|
3.13
|
|
5
|
Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition.
|
J Am Soc Nephrol
|
2011
|
2.60
|
|
6
|
Sirolimus therapy to halt the progression of ADPKD.
|
J Am Soc Nephrol
|
2010
|
2.42
|
|
7
|
Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial.
|
Lancet
|
2004
|
2.38
|
|
8
|
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.
|
Lancet
|
2013
|
2.23
|
|
9
|
Combined kidney and liver transplantation for familial haemolytic uraemic syndrome.
|
Lancet
|
2002
|
2.12
|
|
10
|
The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.
|
Kidney Int Suppl
|
2005
|
2.10
|
|
11
|
Rituximab for idiopathic membranous nephropathy.
|
Lancet
|
2002
|
2.03
|
|
12
|
von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
|
Blood
|
2002
|
1.85
|
|
13
|
The GFR and GFR decline cannot be accurately estimated in type 2 diabetics.
|
Kidney Int
|
2013
|
1.81
|
|
14
|
Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.
|
J Am Soc Nephrol
|
2007
|
1.76
|
|
15
|
ACE inhibition is renoprotective among obese patients with proteinuria.
|
J Am Soc Nephrol
|
2011
|
1.70
|
|
16
|
Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
|
Gastroenterology
|
2013
|
1.66
|
|
17
|
Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial.
|
Blood
|
2012
|
1.58
|
|
18
|
Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.
|
J Am Soc Nephrol
|
2006
|
1.56
|
|
19
|
Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy.
|
Clin J Am Soc Nephrol
|
2007
|
1.49
|
|
20
|
Doppler ultrasonography in posttransplant renal artery stenosis: a reliable tool for assessing effectiveness of revascularization?
|
Transplantation
|
2003
|
1.47
|
|
21
|
Overview of randomised trials of ACE inhibitors.
|
Lancet
|
2006
|
1.46
|
|
22
|
Proteinuria should be used as a surrogate in CKD.
|
Nat Rev Nephrol
|
2012
|
1.42
|
|
23
|
Effect of high dose ramipril with or without indomethacin on glomerular selectivity.
|
Kidney Int
|
2002
|
1.42
|
|
24
|
In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: insights from the MY.S.S. trial.
|
Kidney Int
|
2004
|
1.42
|
|
25
|
Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion.
|
Diabetes
|
2006
|
1.40
|
|
26
|
Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.
|
Clin J Am Soc Nephrol
|
2010
|
1.36
|
|
27
|
Liver-kidney transplantation to cure atypical hemolytic uremic syndrome.
|
J Am Soc Nephrol
|
2008
|
1.34
|
|
28
|
Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study.
|
Am J Nephrol
|
2011
|
1.30
|
|
29
|
The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.
|
Nephrol Dial Transplant
|
2003
|
1.30
|
|
30
|
Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition.
|
Ann Intern Med
|
2002
|
1.28
|
|
31
|
Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy.
|
Kidney Int
|
2004
|
1.26
|
|
32
|
Transplant renal artery stenosis.
|
J Am Soc Nephrol
|
2004
|
1.24
|
|
33
|
Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation.
|
Am J Transplant
|
2005
|
1.23
|
|
34
|
Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
|
Kidney Int
|
2003
|
1.21
|
|
35
|
Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection.
|
Am J Kidney Dis
|
2003
|
1.09
|
|
36
|
Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study.
|
Nephron Clin Pract
|
2010
|
1.06
|
|
37
|
Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.
|
J Am Soc Nephrol
|
2005
|
1.06
|
|
38
|
Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT.
|
Diabetes
|
2009
|
1.05
|
|
39
|
Developing regulatory-compliant electronic case report forms for clinical trials: experience with the demand trial.
|
J Am Med Inform Assoc
|
2009
|
1.05
|
|
40
|
Strategies for national health care systems in emerging countries: the case of screening and prevention of renal disease progression in Bolivia.
|
Kidney Int Suppl
|
2005
|
0.99
|
|
41
|
Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial.
|
Lancet
|
2002
|
0.99
|
|
42
|
Sirolimus for calcineurin inhibitors in organ transplantation: contra.
|
Kidney Int
|
2010
|
0.99
|
|
43
|
Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectives.
|
Curr Diabetes Rev
|
2011
|
0.98
|
|
44
|
In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development.
|
J Immunol
|
2013
|
0.96
|
|
45
|
Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy.
|
J Am Soc Nephrol
|
2011
|
0.96
|
|
46
|
Outcome of renal transplantation from very old donors.
|
N Engl J Med
|
2009
|
0.96
|
|
47
|
ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome.
|
J Am Soc Nephrol
|
2009
|
0.94
|
|
48
|
Rituximab in primary membranous nephropathy: first-line therapy, why not?
|
Nephron Clin Pract
|
2014
|
0.91
|
|
49
|
Proteinuria: Is the ONTARGET renal substudy actually off target?
|
Nat Rev Nephrol
|
2009
|
0.91
|
|
50
|
Kidney failure stabilizes after a two-decade increase: impact on global (renal and cardiovascular) health.
|
Clin J Am Soc Nephrol
|
2006
|
0.90
|
|
51
|
PPARγ2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies.
|
Nephrol Dial Transplant
|
2011
|
0.89
|
|
52
|
Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN).
|
Kidney Int Suppl
|
2004
|
0.88
|
|
53
|
Worsening kidney function in decompensated heart failure: treat the heart, don't mind the kidney.
|
Eur Heart J
|
2011
|
0.87
|
|
54
|
The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension.
|
Blood Press
|
2007
|
0.86
|
|
55
|
Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy.
|
Nephrol Dial Transplant
|
2005
|
0.86
|
|
56
|
Insulin resistance and proliferative retinopathy: a cross-sectional, case-control study in 115 patients with type 2 diabetes.
|
J Clin Endocrinol Metab
|
2004
|
0.86
|
|
57
|
Sirolimus to replace calcineurin inhibitors? Too early yet.
|
Lancet
|
2009
|
0.85
|
|
58
|
Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
|
J Am Soc Nephrol
|
2004
|
0.85
|
|
59
|
Halting the progression of chronic nephropathy.
|
J Am Soc Nephrol
|
2002
|
0.85
|
|
60
|
Dealing with renin-angiotensin inhibitors, don't mind serum creatinine.
|
Am J Nephrol
|
2012
|
0.84
|
|
61
|
Monitoring initial response to Angiotensin-converting enzyme inhibitor-based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trials.
|
Hypertension
|
2010
|
0.84
|
|
62
|
Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: a hypothesis.
|
Am J Kidney Dis
|
2013
|
0.83
|
|
63
|
Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism.
|
Pharmacogenet Genomics
|
2009
|
0.82
|
|
64
|
Preventing microalbuminuria in patients with type 2 diabetes.
|
Diabetes Metab Res Rev
|
2007
|
0.82
|
|
65
|
Cyclosporine prolongs delayed graft function in kidney transplantation: are rabbit anti-human thymocyte globulins the answer?
|
Nephron Clin Pract
|
2005
|
0.82
|
|
66
|
Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study.
|
Eur J Dermatol
|
2006
|
0.81
|
|
67
|
ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection?
|
J Am Soc Nephrol
|
2004
|
0.81
|
|
68
|
ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy.
|
Diabetes
|
2013
|
0.81
|
|
69
|
Old donors for kidney transplantation: how old?
|
Gerontology
|
2010
|
0.81
|
|
70
|
Progression, Remission and Regression of Chronic Renal Diseases.
|
Nephron
|
2016
|
0.81
|
|
71
|
Successes and disappointments with clinical islet transplantation.
|
Adv Exp Med Biol
|
2010
|
0.80
|
|
72
|
Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy.
|
Hypertension
|
2010
|
0.80
|
|
73
|
Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
|
Clin J Am Soc Nephrol
|
2010
|
0.80
|
|
74
|
Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination.
|
Vasc Health Risk Manag
|
2007
|
0.80
|
|
75
|
Intensified inhibition of renin-angiotensin system: a way to improve renal protection?
|
Curr Hypertens Rep
|
2007
|
0.80
|
|
76
|
Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis.
|
Am J Nephrol
|
2011
|
0.80
|
|
77
|
Tackling the shortage of donor kidneys: how to use the best that we have.
|
Am J Nephrol
|
2003
|
0.79
|
|
78
|
Thrombotic microangiopathy in renal transplantation.
|
Ann Transplant
|
2002
|
0.79
|
|
79
|
Mechanisms of progression of chronic renal disease.
|
Saudi J Kidney Dis Transpl
|
2008
|
0.78
|
|
80
|
Renal hemodynamics and renoprotection.
|
Nephron Clin Pract
|
2008
|
0.78
|
|
81
|
Chronic nephropathies: individual risk for progression to end-stage renal failure as predicted by an integrated probabilistic model.
|
Nephron Clin Pract
|
2003
|
0.78
|
|
82
|
Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny.
|
Nephron
|
2014
|
0.78
|
|
83
|
The diabetic CKD patient--a major cardiovascular challenge.
|
J Ren Care
|
2010
|
0.78
|
|
84
|
Kidney failure stabilizes after an increase over 2 decades.
|
J Ren Care
|
2009
|
0.78
|
|
85
|
Nonimmunosuppressive therapy of membranous nephropathy.
|
Semin Nephrol
|
2003
|
0.78
|
|
86
|
Novel effective drugs for diabetic kidney disease? or not?
|
Expert Opin Emerg Drugs
|
2014
|
0.78
|
|
87
|
Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade.
|
Expert Opin Pharmacother
|
2005
|
0.77
|
|
88
|
Proteinuria in diabetic nephropathy: treatment and evolution.
|
Curr Diab Rep
|
2003
|
0.77
|
|
89
|
Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level.
|
Kidney Int
|
2003
|
0.77
|
|
90
|
Proteinuria: Increased angiotensin-receptor blocking is not the first option.
|
Nat Rev Nephrol
|
2009
|
0.77
|
|
91
|
Which antihypertensive drugs are the most nephroprotective and why?
|
Expert Opin Pharmacother
|
2010
|
0.76
|
|
92
|
Intensified inhibition of renin-angiotensin system: a way to improve renal protection?
|
Curr Hypertens Rep
|
2009
|
0.76
|
|
93
|
Is mycophenolate mofetil better than azathioprine in organ transplantation?
|
Transplantation
|
2006
|
0.75
|
|
94
|
Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation.
|
J Transplant
|
2012
|
0.75
|
|
95
|
ACP Journal Club. Prednisolone plus chlorambucil preserved renal function in membranous nephropathy.
|
Ann Intern Med
|
2013
|
0.75
|
|
96
|
Oral acetyl-L-carnitine therapy and insulin resistance.
|
Hypertension
|
2010
|
0.75
|
|
97
|
Initial combination therapy for treatment of hypertension.
|
Lancet
|
2011
|
0.75
|
|
98
|
Chronic kidney disease: Staging CKD: can we rely on estimated GFRs?
|
Nat Rev Nephrol
|
2011
|
0.75
|
|
99
|
Islet transplantation: need for a time-out?
|
Nat Clin Pract Nephrol
|
2008
|
0.75
|
|
100
|
Preventing nephropathy in type 2 diabetes.
|
G Ital Nefrol
|
2016
|
0.75
|
|
101
|
Losartan in diabetic nephropathy.
|
Expert Rev Cardiovasc Ther
|
2004
|
0.75
|
|
102
|
Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients.
|
Nephron
|
2016
|
0.75
|
|
103
|
Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics?
|
Curr Hypertens Rep
|
2003
|
0.75
|
|
104
|
Targeting the renin angiotensin system in dialysis patients.
|
Semin Dial
|
2011
|
0.75
|
|
105
|
Hyperhomocysteinemia and increased risk of retinopathy: a cross-sectional, case-control study in patients with type 2 diabetes.
|
Diabetes Care
|
2002
|
0.75
|
|
106
|
The Bergamo Kidney Transplant Program.
|
Clin Transpl
|
2005
|
0.75
|
|
107
|
Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study.
|
Am J Nephrol
|
2015
|
0.75
|
|
108
|
Does remission of renal disease associated with antihypertensive treatment exist?
|
Curr Hypertens Rep
|
2007
|
0.75
|